Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR Year None2024 December 13, 2024 Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis October 24, 2024 Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance August 13, 2024 Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis August 5, 2024 Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology July 30, 2024 Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe July 25, 2024 Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024 April 24, 2024 Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth March 26, 2024 Galderma Announces Full Exercise of Over-Allotment Option